Intellia Therapeutics (NTLA) Price Target: AI vs Analyst Consensus
Our AI model gives Intellia Therapeutics (NTLA) a 6-month price target of $11.22, representing 6% potential downside from the current price of $11.93. The forecast combines financial fundamentals, technical analysis, and 25+ alternative data signals, including hiring trends, web traffic, employee sentiment, and social media activity. Intellia Therapeutics’s current AI Score is 36/100 (Sell).
What’s Driving the NTLA Price Target
These are the signals feeding Intellia Therapeutics’s AI price target — spanning financial fundamentals, technical analysis, and alternative data — grouped by their recent direction. Improving signals tend to support a higher target; declining signals weigh on it.
No signals trending up right now.
NTLA Stock Forecast for 2026
Our AI model gives Intellia Therapeutics (NTLA) a 6-month price target of $11.22 — 6% downside from the current price of $11.93 — implying a decline toward that level through the rest of 2026. The target updates daily as new NTLA financial, technical, and alternative-data signals come in.
NTLA Price Prediction for 2027–2030
AltIndex does not publish a multi-year model — alternative data is most predictive over the next 6–12 months. Extending the current trajectory as a simple linear extrapolation projects NTLA toward $7.20 by 2030, but long-range estimates carry far more uncertainty and should be treated as directional only. The more reliable signal is whether Intellia Therapeutics’s AI Score and the drivers above keep improving over time.
Intellia Therapeutics (NTLA) Monthly Price Forecast
| Month | Forecast | vs Current |
|---|---|---|
| Oct 2026 | $11.81 | -1% |
| Nov 2026 | $11.69 | -2% |
| Dec 2026 | $11.58 | -3% |
| Jan 2027 | $11.46 | -4% |
| Feb 2027 | $11.34 | -5% |
| Mar 2027 | $11.22 | -6% |
Straight-line projection from the latest price ($11.93) toward our 6-month AI target of $11.22. An estimate, not a month-by-month model.
See how AltIndex’s AI Score picks have performed →Similar companies
View All →
Frequently Asked Questions: Intellia Therapeutics Price Prediction
On September 9, Intellia Therapeutics (NTLA) was assigned a Sell signal with a target price of $11.22. This signal was predicated on several factors, including a long-term decrease in job posts, and a worryingly low business outlook across the company's employees.
The conviction in the pick is medium-low due to the fairly restrained amount of alternative data available.
Based on Alternative Data, Intellia Therapeutics is a sell.
Based on our Alternative data analysis, it's advisable to consider selling Intellia Therapeutics (NTLA) stock. The observed negative trends all contribute to a sell signal. However, this information should not be considered financial advice. Like any investment choice, it's important to conduct comprehensive research, not only utilizing alternative data, but also considering the company's financials, industry trends, and recent news developments.
With an AI score of 36, the NTLA stock forecast indicates a potential decline.
To predict the price for NTLA in 2027, we can extrapolate the AI price target. This approach projects NTLA's price to reach $11.46.
To predict the price for NTLA in 2030, we can again extrapolate the AI price target. This approach projects NTLA's price to reach $7.2.
When predicting the price for NTLA, our approach incorporates multiple scores assessing different aspects of the company. The Brand score measures growth and engagement across social media channels, indicating audience reach. The Employee score evaluates workforce health, considering job postings, business outlook, and employee ratings. The Customer score examines engagement on websites, app downloads, and sentiment in stock forums. Lastly, the Fundamental score analyzes financial statements and analyst ratings. By evaluating this data, we gain a holistic view of the company's performance, enabling more informed price predictions.
Based on technical analysis of how the price has moved over the last 6 months, the likelihood of the price going up tomorrow is 43%. Note that this is a simplistic analysis and should be used with caution, as prices are influenced by a myriad of factors.
Know the moment Intellia Therapeutics’s price target changes
Get NTLA alerts
